Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone MASH Trial after Hepatectomy (PMASH Trial)
jRCTs051260025Recruiting
- Sponsor
- Nara Medical University
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pioglitazone in hepatocellular carcinoma (HCC) and metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Nara Medical University. Started Jul 2026; status: recruiting.
02
Drugs
pioglitazone
03
Conditions
hepatocellular carcinoma (HCC)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCTs051260025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051260025.